PMID- 21787235
OWN - NLM
STAT- MEDLINE
DCOM- 20120214
LR  - 20211020
IS  - 1521-0499 (Electronic)
IS  - 0190-2148 (Print)
IS  - 0190-2148 (Linking)
VI  - 37
IP  - 7
DP  - 2011 Sep
TI  - Green tea epigallo-catechin-galleate ameliorates the development of obliterative 
      airway disease.
PG  - 435-44
LID - 10.3109/01902148.2011.584359 [doi]
AB  - Lung transplantation has the worst outcome compared to all solid organ 
      transplants due to chronic rejection known as obliterative bronchiolitis (OB). 
      Pathogenesis of OB is a complex interplay of alloimmune-dependent and 
      -independent factors, which leads to the development of inflammation, fibrosis, 
      and airway obliteration that have been resistant to therapy. The 
      alloimmune-independent inflammatory pathway has been the recent focus in the 
      pathogenesis of rejection, suggesting that targeting this may offer therapeutic 
      benefits. As a potent anti-inflammatory agent, epigallo-catechin-galleate (EGCG), 
      a green tea catechin, has been very effective in ameliorating inflammation in a 
      variety of diseases, providing the rationale for its use in this study in a 
      murine heterotopic tracheal allograft model of OB. Mice treated with EGCG had 
      reduced inflammation, with significantly less neutrophil and macrophage 
      infiltration and significantly reduced fibrosis. On further investigation into 
      the mechanisms, inflammatory cytokines keratinocyte (KC), interleukin-17 (IL-17), 
      and tumor necrosis factor-alpha (TNF-alpha), involved in neutrophil recruitment, were 
      reduced in the EGCG-treated mice. In addition, monocyte chemokine monocyte 
      chemoattractant protein-1 (MCP-1) was significantly reduced by EGCG treatment. 
      Antifibrotic cytokine interferon-gamma-inducible protein-10 (IP-10) was increased and 
      profibrotic cytokine transforming growth factor-beta (TGF-beta) was reduced, further 
      characterizing the antifibrotic effects of EGCG. These findings suggest that EGCG 
      has great potential in ameliorating the development of obliterative airway 
      disease.
FAU - Liang, Olin D
AU  - Liang OD
AD  - Department of Medicine, Division of Respiratory Diseases, Children's Hospital 
      Boston, Harvard Medical School, Boston, Massachusetts, USA.
FAU - Kleibrink, Bjoern E
AU  - Kleibrink BE
FAU - Schuette-Nuetgen, Katharina
AU  - Schuette-Nuetgen K
FAU - Khatwa, Umakanth U
AU  - Khatwa UU
FAU - Mfarrej, Bechara
AU  - Mfarrej B
FAU - Subramaniam, Meera
AU  - Subramaniam M
LA  - eng
GR  - K08 HL084242/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20110725
PL  - England
TA  - Exp Lung Res
JT  - Experimental lung research
JID - 8004944
RN  - 0 (Cytokines)
RN  - 0 (Tea)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
SB  - IM
MH  - Animals
MH  - Bronchiolitis Obliterans/*drug therapy/etiology/pathology
MH  - Catechin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Cytokines
MH  - Fibrosis/prevention & control
MH  - Inflammation/drug therapy
MH  - Lung Transplantation/adverse effects
MH  - Mice
MH  - Neutrophil Infiltration
MH  - Tea
PMC - PMC4372092
MID - NIHMS671576
COIS- Declaration of interest: The authors report no conflicts of interest. The authors 
      alone are responsible for the content and writing of the paper.
EDAT- 2011/07/27 06:00
MHDA- 2012/02/15 06:00
PMCR- 2015/03/24
CRDT- 2011/07/27 06:00
PHST- 2011/07/27 06:00 [entrez]
PHST- 2011/07/27 06:00 [pubmed]
PHST- 2012/02/15 06:00 [medline]
PHST- 2015/03/24 00:00 [pmc-release]
AID - 10.3109/01902148.2011.584359 [doi]
PST - ppublish
SO  - Exp Lung Res. 2011 Sep;37(7):435-44. doi: 10.3109/01902148.2011.584359. Epub 2011 
      Jul 25.